How long do Mounjaro side effects last?

Mounjaro (tirzepatide) is a once-weekly injection used in adults to support medical weight management and to treat type 2 diabetes. Like any GLP-1-based treatment, it changes how the gut signals fullness — which is much of how it works, and also why side effects in the first weeks of a new dose are common. Knowing the typical timeline, what is normal, and what is not, makes the early phase of treatment much easier to live with.

Which side effects are common in the first weeks

The side effects most often described by patients in the first weeks of Mounjaro treatment are gastrointestinal. They are listed in the UK Summary of Product Characteristics and in the BNF entry for tirzepatide, and they tend to cluster as a recognisable pattern:

• Nausea — usually mild to moderate, sometimes more noticeable on or just after the injection day
• Reduced appetite — part of the medicine's intended action, but it can feel like a side effect early on
• Constipation, or less commonly loose stools
• Mild burping, reflux, or a "full" feeling after small meals
• Fatigue or a low-grade "off" feeling for a few days
• Injection-site reactions — usually a small area of redness or itch that settles quickly

For most people, these are inconvenient but tolerable. Less common reactions include headache, dizziness, and a metallic or altered taste. Tirzepatide acts on receptors that influence gastric emptying, so the upper digestive tract is where the body first "feels" the medicine — that is the reason side effects are weighted there rather than spread across other systems.

Typical duration after starting and after dose increases

The most useful timeline to hold in mind is this: side effects tend to peak in the first one to two weeks after any dose change, and most settle within two to four weeks as the body adapts. That same pattern repeats — in a usually milder form — at every step up the dose ladder.

A common picture across the first few months looks something like this:

• Week 1 (2.5 mg starter): nausea and appetite suppression are most noticeable. Constipation may start to build.
• Weeks 2–4 (2.5 mg): nausea typically eases. Appetite stays reduced. Constipation may continue if fluid and fibre are low.
• Week 5 (step up to 5 mg): a return of nausea for a few days to a week is common, usually milder than the very first week.
• Weeks 6–8 (5 mg): most patients settle into a routine. Reflux, burping and mild nausea may persist at a low level.
• Subsequent step-ups: the same short flare-and-settle pattern at each new strength.

Tirzepatide takes around four weeks to reach steady state at any given dose. That biological half-life is the reason UK prescribers usually hold each step for at least four weeks before considering another change — it gives both the body and the clinician a clear read on what is happening before another move.

Individual variation is real and expected. Some patients have very little nausea at any point; others find the first month uncomfortable but the rest of the journey smooth. A small group has more persistent symptoms even at a stable dose. Comparing your experience to averages is useful as a frame, but your clinician will base decisions on your specific picture, not the textbook curve.

Practical guidance for getting through the early weeks

Most clinicians share a similar set of practical steps that make the first weeks of any dose easier:

• Smaller, more frequent meals. Large portions are physically harder to manage on a medicine that slows gastric emptying. Three smaller meals plus a small snack often works better than two large ones.
• Prioritise protein and fibre. Both blunt nausea, slow blood-sugar swings, and reduce the chance of constipation. Aiming for a palm-sized portion of protein and a fist of vegetables at each meal is a useful default.
• Drink water steadily through the day. Appetite suppression often blunts thirst signals too, so dehydration creeps in quietly — and even mild dehydration makes nausea worse.
• Be cautious with very rich or high-fat meals in the first two weeks of any new dose. Fat slows gastric emptying further, and the combination is often what triggers the worst nausea.
• Plan your injection day around your routine. If you tend to feel effects strongly the day after, schedule the injection so the next day is quieter.
• Stay gently active. A short walk after meals helps both digestion and constipation more than rest does.
• Watch for constipation early. A fibre source at every meal, plus fluids, prevents most cases. If it builds anyway, a community pharmacist can advise on a short course of a stimulant or osmotic laxative.

If nausea is significant, your clinician may consider a short course of an anti-emetic — options used in this context include ondansetron or prochlorperazine. This is a clinical decision, not a routine over-the-counter step. The right choice depends on your medical history, any other medications, and the pattern of nausea.

Crucially: do not adjust your own Mounjaro dose to manage side effects. Stepping back down to a previous dose can be a valid clinical option, but it should be a conversation with your prescriber, not a self-decision. Self-adjusting risks losing track of where you are in the schedule and removes the safety check that a clinician's review provides.

Side effects that warrant urgent review

Most side effects are mild, time-limited and self-managing. A small number are not. The BNF entry and the SmPC list several reactions that need urgent clinical attention rather than waiting for them to settle.

Speak to a clinician promptly, or seek urgent care, if you have:

• Severe or persistent abdominal pain, especially if it radiates to the back or comes with vomiting. This pattern can signal pancreatitis and is the most important red flag with any GLP-1 medicine.
• Persistent vomiting that stops you keeping fluids down, or signs of severe dehydration — dark urine, dizziness on standing, very dry mouth.
• Right-upper abdominal pain, fever, or jaundice (yellowing of skin or eyes). Gallbladder events are a recognised, uncommon risk with GLP-1 medicines.
• Signs of an allergic reaction — facial or throat swelling, breathing difficulty, widespread rash.
• Symptoms of hypoglycaemia — sweating, shakiness, confusion — particularly if you are also taking insulin or a sulfonylurea for diabetes.
• New or worsening kidney problems, such as a large drop in urine output.

For true emergencies in the UK call 999. For urgent advice that is not an emergency, contact your prescriber, your GP, or NHS 111. Always mention that you are on tirzepatide — it changes how some symptoms are interpreted.

What to expect at higher maintenance doses

Once you settle on a maintenance dose, the early-treatment side-effect curve is usually behind you. Patients tend to report one of three patterns: side effects fade almost completely, leaving only occasional mild appetite changes; low-grade nausea or constipation persists at a level manageable with diet and hydration; or, less commonly, side effects remain bothersome enough that a different dose or different treatment is the more sensible answer.

At higher doses (10 mg, 12.5 mg, 15 mg), the chance of nausea after a step-up does not necessarily get worse — but if it does, that is useful information for your clinician. Many patients find a slightly lower maintenance dose offers most of the clinical benefit with significantly fewer side effects, and a clinician-led step back down is a recognised, evidence-aligned option. The licensed maximum of 15 mg is not where every patient should aim; the right dose is the one that gives sustained progress towards your agreed clinical goals with tolerable side effects.

Persistent reflux, gradual weight regain on a low dose, or a new symptom several months into treatment all deserve a review. They are not necessarily reasons to stop the medicine, but they are reasons to look at the picture again. For longer-term context on the UK approach to GLP-1 treatment, the NICE guidance and MHRA safety updates are useful background; your Farmeci clinician will draw on both at each review.

Working with your Farmeci clinician on tolerability

In a Farmeci programme, you have regular review with a UK-registered prescriber — usually around every four weeks while you are titrating. The point of those reviews is not just to confirm the next dose; it is also to map your side-effect picture honestly and decide what to do with it. Patients who do best on GLP-1 treatment tend to be the ones who treat tolerability as part of the conversation, not as a problem to push through alone.

Useful things to bring to each review: what side effects you have had, how long each lasted, what made them better or worse, anything you tried (over-the-counter remedies, diet changes, timing changes) and how it went. Even small details — that nausea is worse on the third day after your injection, that constipation has been steady for three weeks, that reflux only happens with certain meals — help your clinician make the next decision well. For related context on the standard titration schedule, see our piece on when to increase your Mounjaro dose for weight loss, and on what to do if response slows our piece on why you may not be losing weight on Mounjaro.